Temozolomide with or without WSD0922-FU for EGFR-mutant, IDH-wildtype glioblastoma
Official title: Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This trial tests whether adding a drug called WSD0922-FU to temozolomide helps slow this brain tumor down.
Read our full plain-language summary
What the trial team says
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. WSD0922-FU is a targeted treatment which blocks EGFR. It is able to get into the brain and spinal cord and help treat those types of tumors. Adding WSD0922-FU to the usual treatment with temozolomide may be more effective in slowing disease progression, compared to temozolomide alone, in patients with EGFR-mutant, IDH-wildtype glioblastoma.
Key facts
- Registry number
- NCT07708961
- Stage of testing
- Phase 2
- Conditions studied
- Glioblastoma, IDH-Wildtype
Where it is running
This trial lists 3 sites.
-
Arizona
- Mayo Clinic in Arizona (Scottsdale)
-
Florida
- Mayo Clinic in Florida (Jacksonville)
-
Minnesota
- Mayo Clinic in Rochester (Rochester)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.